Intellia Therapeutics Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
Intellia shares drop 4% despite phase III data meeting all endpoints. The company begins a rolling FDA filing.
Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial
Intellia Therapeutics said on Monday its experimental therapy for a rare genetic disorder has met the main goal in a late-stage study.
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition succeeded in a Phase 3 trial, a landmark for gene editing. The treatment uses Nobel Prize-winning Crispr technology to edit DNA and treat hereditary angioedema, a condition that causes potentially life-threatening swelling attacks.
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know
Intellia stock climbs nearly 20% in three months as pipeline progress, lifted FDA holds, and late-stage study updates boost investor optimism.
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
NTLA shares jump after fourth-quarter earnings and revenues exceed expectations. The company focuses on lonvo-z and nex-z pipeline programs.
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold
Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average
Intellia Therapeutics, Inc. (NTLA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NTLA broke through the 200-day moving average, which suggests a long-term bullish trend.
Intellia Stock Declines Around 55% in 3 Months: Here's Why
NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.
